Anal squamous cell carcinomas (ASCC) are increasing in frequency across the developed world ([@bib17]; [@bib57]; [@bib3]). Associated with oncogenic subtypes of the human papilloma viruses (HPV; [@bib1]) they typically present at a localised stage with or without regional lymph node involvement. Aside from in the earliest tumours, where the majority may be excised surgically, the international standard of care is chemoradiotherapy (CRT). As first appreciated by Nigro *et al*, ASCC demonstrate marked sensitivity to this combined modality of treatment, which additionally avoids the need for radical surgery and permanent colostomy ([@bib33]). Although 6 phase III clinical trials have been reported in ASCC investigating alternative chemotherapies, there is no benefit from adjuvant or maintenance chemotherapy and concurrent chemoradiotherapy with Mitomycin, and 5FU remains the standard of care with 65--74% 3-year local control ([@bib49]). However, all have posed clinical questions without any correlative biology or stratification beyond clinical and stage-related prognostic markers.

It is increasingly appreciated that the biology of HPV transformation contributes to the chemo/radio sensitivity seen in ASCC, a characteristic most extensively investigated in head and neck cancer ([@bib52]). An improved understanding of the underlying factors involved in this process, and those that mediate resistance and relapse would offer significant opportunities in improving outcomes across the spectrum of ASCC. Furthermore, as we will detail, ASCC as a model system might provide further insights into cancer biology across the spectrum of HPV-associated malignancies.

Translational questions in anal cancer
======================================

While the relative sensitivity of ASCC to CRT means that oncologic outcomes appear reasonable, key translational questions remain and for certain groups of patients, outcomes remain poor. Although data around late toxicity from anal cancer CRT is limited ([@bib2]) up to 30% patients experience debilitating side effects, particularly in terms of bowel function. Surgery is currently reserved for relapsing cases, where there is a clear benefit to operating early ([@bib41]) and as such prompt detection of residual/recurrent disease, or even identification of tumours that are primarily resistant to CRT would have significant clinical benefit.

In terms of utilising biomarkers to improve outcomes, first, factors that are predictive of response would facilitate modulation of components of CRT (i.e., radiotherapy dose or novel combination therapeutics) either aiming to improve response rates in poor risk disease, or potentially de-intensify treatment to avoid excessive late toxicity (as currently being tested in the setting of head and neck cancers ([@bib37])). There is considerable variation in radiotherapy doses used, from the relatively lower doses in the initial series ([@bib33]), through 50.4 Gy in ACT2 to 54--64 Gy in the Nordic countries ([@bib24]). Second techniques that aided the early detection of relapse would facilitate prompt salvage surgery with improved outcomes.

In addition, there is the potential to investigate whether underlying genomic factors modulate HPV-induced transformation of cells ([@bib25]) and subsequent clinical behaviour or mediate toxicity from radiotherapy as described in prostate cancer ([@bib9]). An understanding of the mechanisms that mediate relapse, dissemination and resistance will identify technology and targets for future therapy in a disease where currently there is only palliative cytotoxic chemotherapy with limited response rates and poor outcomes.

Importantly, given the ultimate aim of developing any biomarker is to improve clinical outcomes, it is vital that tests are sufficiently robust and reproducible in terms of assay development, and then prospectively validated, ideally in the context of a randomised controlled trial, as detailed in Cancer Research UK\'s biomarker roadmap; (<http://www.cancerresearchuk.org/sites/default/files/prognostic_and_predictive.pdf>).

Current biomarkers of response to chemoradiotherapy
===================================================

A number of variables are reported to contribute to the heterogeneity in outcomes seen in patients with ASCC ([@bib7]). These include measurement of the extent of a patient\'s disease as conferred by the tumour size and nodal status, each of which independently predicts disease-free and overall survival (OS). It has also been reported that initial response to treatment with radiotherapy correlates with the extent of both local control and OS. However, despite their overall prognostic value, clinicopathologic factors do not consistently enable prediction of response to currently available treatment modalities. There therefore remains a requirement for predictive markers to guide clinicians\' choice of treatment.

In a previous systematic review of 21 studies published before 2010, Lampejo *et al* identified 13 biomarkers associated with outcome in ASCC ([@bib23]). Of these, only p53 and p21 were shown to have prognostic utility in more than one study, yet their value was not universally supported by the reported literature. Other reported prognostic biomarkers -- testable markers postulated to provide information relating to a patient\'s outcome -- included numerous tumour suppressor genes, apoptotic regulators, tumour markers and factors involved in angiogenesis, proliferation and invasion.

A number of subsequent retrospective analyses have highlighted the potential prognostic utility of identifying tumour HPV involvement, either directly or through analysis of its surrogate marker, p16 overexpression. A systematic search of PubMed (August 2006--August 2016) using the terms: p16 AND/OR HPV/human papilloma virus AND outcome OR prognosis/prognostic AND anal squamous cell carcinoma OR anal carcinoma was performed. Only those relating to the specific prognostic utility of HPV/p16 in anal squamous cell carcinoma patients managed with chemoradiotherapy were selected. References of those papers selected to be of potential relevance based on their abstract were also reviewed.

As shown in [Table 1](#tbl1){ref-type="table"}, OS, recurrence and both locoregional and systemic failure are reported to correlate with high p16 expression and the presence of HPV DNA. Given that the prevalence of HPV DNA is universally reported to be high, additional prognostic subsets have been generated through the detection of the specific HPV genotype HPV16, either alone or in combination with p16.

The most widely studied outcome with respect to HPV/p16 status is OS. In univariate analyses, significant associations have been reported between 3- to 10-year survival and both p16 expression and the detection of HPV and HPV16 DNA. There nevertheless remain inconsistencies and in the studies included here, p16 status significantly correlated with OS in only half of the patient populations in which it was analysed. Though reported in fewer manuscripts, both recurrence and locoregional failure have also been consistently significantly associated with HPV, HPV16 and p16 status. This is in contrast to systemic failure, which to our knowledge significantly correlates with HPV/p16 status in only two reports to date.

In multivariate analyses, HPV16 and p16 are both reported to be independently predictive of PFS and OS ([@bib59]; [@bib12]; [@bib40]; [@bib47]; [@bib1]; [@bib26]; [@bib42]). Mai *et al* additionally report an independent association between combined HPV/p16 status and PFS ([@bib26]). In contrast, Koerber and Meulendijks identified no independent associations for HPV or p16 alone, but reported combined HPV and p16 to be predictive of both PFS and OS ([@bib21]; [@bib30]).

The studies outlined here are retrospective and small. Median follow-up ranges between 27.9--59.0 months, over which time the outcomes of between 47 and 110 patients were studied. This may contribute to the inconsistencies in the outcomes reported here. However, given that the majority of tumours are HPV positive (noting that not all HPV DNA-positive ASCC, and particularly those solely p16-positive, can be causally related to HPV ([@bib39]) where the gold standard to indicate a transcriptionally active (transforming) HPV infection is detection of E6/E7 mRNA ([@bib54])) additional biomarkers over and above HPV status are required to guide treatment stratification.

Molecular mechanisms for differential sensitivity to CRT in HPV± cases
======================================================================

Improved technologies (predominately next generation sequencing) have begun to offer explanations for the differential sensitivities seen between HPV+ and −ve tumours, accepting the subtleties of this distinction as detailed above. As previously discussed, increased protein expression of p53 (associated with mutations that cause the protein to remain detectable) has previously been associated with worse outcomes after CRT and is inversely correlated with p16/HPV ([@bib12]). Sequencing data confirms that p53 mutations and HPV involvement are for the most part mutually exclusive in ASCC ([@bib30]) being found in HPV−ve cases in a manner parallel to that seen in head and neck cancer ([@bib56]). Inactivation of p53 seems to be an essential step in tumourigenesis. In HPV+ve tumours this arises through the action of HPV E6, though potentially this can be overcome if sufficient DNA damage (i.e.,CRT) occurs. In the absence of E6 (i.e., HPV−ve cases), such suppression of activity must arise through mutation, meaning p53 activity is unrecoverable and DNA damage goes undetected ([Figure 1](#fig1){ref-type="fig"}).

A number of studies have used broader genomic profiling to investigate cohorts of ASCC, using a mixture of pre-treatment biopsies and samples from relapsing patients. A combination of immunohistochemistry*, in situ* hybridisation and targeted sequencing was applied to 199 ASCC ([@bib48]). A total of 89% cases expressed EGFR, though amplification was infrequent (7.4%) and no mutations were recorded. The most commonly mutated gene was PIK3CA (33% samples) with TP53 second most frequent in 15%. Further evidence of the high frequency of these mutations comes from data (using a 236 gene NGS panel) from 70 anal cancers ([@bib6]). In total, 87% were HPV positive. The most frequent mutations again involved PIK3CA (40% cases), with PTEN loss seen in an additional 14%. TP53 and CDKN2a mutations were seen predominately in HPV negative cases where 6/9 tumours had mutations in TP53 mutation, and 5/9 CDKN2A. Five cases (all HPV+ve) had amplification at 11q13 (a region that includes FGF3, FGF4, FGF19 and CCND1). No associations between these molecular abnormalities and tumour stage or clinical behaviour were reported.

A recent study ([@bib4]) provides further evidence for these relationships, sequencing 8 genes (KRAS, NRAS, HRAS, BRAF, PIK3CA, MET, TP53 and FBXW7) in 148 ASCC patients including 52 recurrences post CRT. A total of 30 patients (20.3%) demonstrated PIK3CA mutations and 7 patients (4.7%) demonstrated mutations in TP53, the latter only seen in recurrent tumours and associated with HPV−ve tumours (3/131 HPV+ve *vs* 4/17 HPV−ve). Three had mutations in KRAS whereas NRAS, HRAS and BRAF were wild-type throughout.

The importance of PI3 kinase signalling in ASCC, predominately through a high frequency of activating PIK3CA mutations, is a feature of other HPV-associated squamous cell carcinomas. In total, 30% cervical cancers harbour PIK3CA mutations associated with poor outcomes following chemoradiotherapy ([@bib29]; [@bib8]), but similar findings are also reported in vulval ([@bib53]) and penile cancers ([@bib28]). Similarly the inverse relationship between HPV involvement and TP53 mutations is documented in HNSCC ([@bib56]) and vulval cancer ([@bib53]).

Host immune response and outcome from CRT
=========================================

The mutational profiling demonstrates differing routes to transformation (HPV±) that appear to impact on clinical outcomes. However, the host response to ASCC is also a powerful arbiter of the effectiveness of CRT. One phenotypic readout of the local immune response can be seen in the extent of infiltration of lymphocytes into the tumour. Measurement of tumour infiltrating lymphocytes (TIL) adds prognostic value to HPV status in head and neck cancer ([@bib55]), where patients with HPV+ve tumours but low levels of TILs had similar outcomes (PFS and OS) as HPV−ve cases. In HPV+ve HNSCC cases TIL status outperformed smoking and T-stage as prognostic variables. Importantly, from a mechanistic perspective, these cohorts included patients with HNSCC treated with surgery, suggesting a prognostic effect of both HPV status and TIL across treatment modalities (and hence not simply related to sensitivity to CRT through TP53 mutations as discussed earlier).

Parallel findings have been demonstrated in ASCC ([@bib11]). Using cohorts of ASCC from the UK and Denmark treated with CRT with published clinical outcomes and known HPV status ([@bib12]; [@bib47]), high levels of TIL showed improved outcomes in the HPV+ve patients, whereas patients with low levels of TIL had outcomes more in keeping with HPV−ve tumours. This finding requires validation in a cohort of samples large enough for robust multivariate analysis to include all clinical and radiological factors but raises the possibility that modulating the host response to the tumour could improve therapeutic response.

Lymphocyte infiltrates represent a visual readout of the local host response, but a more detailed understanding (e.g., relative CD4/CD8 and antibody responses) of the nature of this response should facilitate improved prognostic ability and important opportunities for therapeutic intervention.

Plasma-based monitoring of disease
==================================

Anal Cancer presents a compelling case for developing serial, non-invasive markers of response/relapse, given that the tumour is treated *in situ* with chemoradiotherapy, and may go on to display a complete response only after many months of follow up ([@bib13]). Surgical salvage is possible, but undesirable if a complete response is achieved. Predictive markers that allow real time analysis (and may be prospectively compared with imaging results) would be of significant clinical benefit. For those tumours with residual/recurrent active disease, prompt surgical salvage is associated with improved outcomes ([@bib41]); the prognosis following R1 resection is poor.

Squamous Cell Carcinoma Antigen (SCCA) is a member of the Serpin supergroup of proteins and raised plasma levels have been reported across a number of squamous cancers including cervix, head and neck. With respect to anal cancer, levels at baseline have been reported to have prognostic value. Specifically 49% of 174 patients demonstrated raised plasma SCCA ([@bib58]) at presentation, correlating with reduced complete response to treatment and reduced disease-free and OS. More recently there has been interest in SCCA in follow up where one small study of 24 patients was not consistent with respect to baseline prognosis, but during follow up, 2 patients demonstrated a rise of SCCA, one of whom developed recurrence and metastatic disease ([@bib16]).

More advanced techniques to use plasma-based assays that inform on the biology of disease are now coming of age (O\'Leary and Turner, 2016) where changes in circulating tumour DNA may be a more sensitive and specific way to predict outcome to therapy through treatment ([@bib10]). Longitudinal analysis of cell free DNA is of particular interest, as HPV DNA sequences, integrated into the genomes of anal cancer, represent a unique signature of ongoing cellular activity given the ubiquity of HPV in this cancer type ([@bib1]). This technique has recently been reported using HPV transcripts in cervical cancer ([@bib5]) and head and neck cancer ([@bib44]) in a parallel setting (post chemo-radiotherapy). Not all HPV-associated tumours harbour integrated viral genomes and additionally some of the tumours at highest risk of relapse will be truly HPV negative, so alternative cfDNA targets will also be required for disease monitoring. Importantly, prospective assessment of such cfDNA in anal cancer is required to define the performance characteristics of these tests as compared with and correlated with differing imaging modalities and follow-up schedules.

Similarly there is evidence that microRNAs are involved in HPV-induced transformation of cells in cervical and head and neck cancers at least ([@bib22]) and potentially mediating response to treatment. By their nature microRNAs are relatively stable and again are being investigated in other HPV-associated tumour types as longitudinal markers of disease state ([@bib50]).

Imaging-based prognostic factors, detection of relapse and future potential
===========================================================================

A comprehensive review of imaging biomarkers for anal cancer is beyond the scope of this review, but clearly approaches to refine treatment plans and optimise response assessment will require integration of both biological and imaging parameters. The role of imaging in treatment stratification and assessment of response/relapse has evolved in recent years reflecting the technological advances that have enabled high resolution anatomical imaging to be combined with functional imaging techniques, exemplified by multi-parametric magnetic resonance imaging (MRI) ([@bib18]) and 18-F fluorodeoxyglucose positron emission tomography (18F-FDG PET) either integrated with computed tomography (CT) ([@bib18]) or more recently with MRI ([@bib15]). Combining the metabolic information from 18F-FDG PET with the high spatial and contrast resolution of anatomical MRI allows accurate delineation of the primary tumour and locoregional nodes for staging and radiotherapy planning, particularly with the incorporation of diffusion-weighted MRI ([@bib27]) and also prognostic information ([@bib31]).

Following therapy, early size-based MRI evaluation (within 8 weeks of completed therapy) has its limitations ([@bib14]) due to co-located radiotherapy changes; however, a tumour regression grade (TRG) score may have promise in identifying patients who would benefit from salvage surgery ([@bib15]). Resolution of 18F-FDG PET activity is effective in detecting complete responders although persistent low grade metabolic activity may not necessarily reflect residual tumour activity (Schwarz *et al*, 2008). More recently imaging radiomic approaches have been investigated as potential imaging biomarkers in the therapy response setting. The texture heterogeneity information captured by these post-processing tools appear to augment current morphological assessment. Greater MRI heterogeneity may be apparent post-therapy in non-responders ([@bib38]), and in the future integrated radiomic approaches combining imaging, clinical and pathological information may allow a more personalised approach to anal cancer management. Again, however, clinical utility will require sufficient levels of quality assurance and reproducibility and validation in prospective studies ([@bib34]).

Ongoing trials and translational opportunities
==============================================

One key question in ASCC is whether the prognostic effect seen through TILs can be manipulated via stimulating the host immune response, either through immune checkpoint inhibition or therapeutic vaccination. Immune checkpoint inhibitors have demonstrated encouraging responses in metastatic ASCC ([@bib36]; [@bib32]). There are a range of potential therapeutic vaccine approaches currently in development ([@bib20]), and clinical trials of one such approach underway in both metastatic and locoregional anal cancer (NCT01671488; A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer). An important component of these studies in ASCC should be to ascertain whether either strategy can elicit increases in the local/systemic immune response where little is currently seen (i.e., improve outcomes in the HPV−ve or TIL low groups) or whether these novel approaches work best in tumours that already elicit a response (i.e., might facilitate reduced intensity treatment).

An alternative approach is to personalise radiotherapy doses by our current understanding of risk, aiming to intensify treatment for poor risk tumours, and test whether lower doses (and potentially less toxicity) can safely be administered to those with a better prognosis. Cancer Research UK has recently funded the PLATO platform of clinical trials (ISRCTN88455282). The three trials, ACT3, 4 and 5, are designed to personalise the use and dose of radiotherapy across the locoregional disease spectrum ([@bib46]). These studies provide an ideal platform for the prospective analysis/validation of a number of the biomarkers discussed here and potentially answer questions around whether increased radiotherapy dose can make up for biologically aggressive features and/or tumours with favourable biology can be cured with less toxic regimens.

Finally, an improved understanding of the molecular biology of anal cancer integrated with associated biomarkers and therapeutic agents might yet allow ASCC patients to benefit from a targeted approach. In the setting of relapsed or metastatic disease, the consistent activation of PI3 kinase signalling through frequent PIK3CA mutation (seen across the HPV-associated tumours) supports the development of clinical trials in this setting. Preclinical data supports this approach with mTOR inhibition showing evidence of efficacy in anal cancer models ([@bib51]). The clinical trial platforms currently being developed can then be adapted to test these approaches as studies and data progress.

A challenge to all these approaches will be in sourcing the biological material to facilitate further understanding and develop biomarker driven trials. A combined approach encouraging additional biopsies (both at diagnosis, during treatment or at relapse), increased use of plasma-based detection and ongoing improvements in technology will be required to maximise output. Achieving this within the context of clinical trials brings the potential to then properly validate such biomarkers to optimise future treatment.

Conclusions
===========

SCCA is a tumour where the primary treatment modality is chemoradiotherapy, with surgery as salvage. As such it provides a model system for comprehensive translational science investigating HPV-associated cellular transformation, staging and stratification of treatment protocols and response assessment with outputs relevant across the spectrum of HPV-associated tumours (oropharynx, cervix, vulva) and beyond.

Our current understanding of prognostic biomarkers offers insights into how biological factors mediate disease progression and response. Integrating this understanding into current and future clinical trials should in the future allow the improved stratification of treatment and facilitate novel therapeutic intervention to improve outcomes for all patients with the disease.
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###### A summary of reported associations between p16 (immunohistochemistry) and HPV status (using PCR), and outcome from anal squamous cell carcinoma treated with chemoradiotherapy

                                                                                                            **Correlation with outcome**[c](#t1-fn5){ref-type="fn"}                                                                                                                                                                       
  -------------------------------------- --------------- --------------------- ----------- ---------------- --------------------------------------------------------- ------------------------------------------------------ ------------------------------------------------------------------------------------------------------------ ---------------------------------------
  [@bib59])                              47 (47 : 53)            51.7          HPV16       66.0 (31/47)     4 year OS rate: *P*=0.008. 84.6% *vs* 39.8%               4-year PFS rate: *P*\<0.001. 63.1% *vs* 15.6%          4-year TTLF rate: *P*=0.006. 76.3% *vs* 36.8%                                                                4-year TTSF rate: NS
                                                                               p16         83.0 (39/47)     NS                                                        4-year PFS: *P*=0.014. 52.5% *vs* 25.0%                4-year TTLF: *P*=0.018. 69.3% *vs* 42.9%                                                                     4-year TTSF rate: NS
  [d](#t1-fn6){ref-type="fn"}[@bib12]    153 (39 : 61)           27.9          p16         89.5 (137/153)   N/A                                                       Relapse rate: *P* = 0.0076. 27.0% *vs* 62.5%           N/A                                                                                                          N/A
  [@bib40]                               50 (26 : 74)            48.0          HPV         84.0 (42/50)     5 year OS: NS                                             5-year PFS: *P* \< 0.01. 92.5 *vs* 50.0%               N/A                                                                                                          N/A
  [@bib21]                               90 (14 : 86)            48.6          HPV         83.3 (75/90)     OS rate: *P*=0.007. 75.8% *vs* 48.0%                      PFS: P \< 0.001. 63.5% *vs* 26.7%                      3-year local control rate: NS                                                                                Risk of distant recurrence: *P*=0.005
                                                                               p16         83.3 (75/90)     OS rate: NS                                               PFS: *P*\<0.0017. 62.3% *vs* 33.3%                     N/A                                                                                                          N/A
                                                                               HPV p16     77.8 (70/90)     OS rate: *P*=0.005. 77.1% *vs* 51.4%                      PFS: *P* \< 0.001. 64.0% *vs* 35.0%                    3-year local control rate: *P*=0.023; 81.0% *vs* 55.9%                                                       N/A
  [e](#t1-fn7){ref-type="fn"}[@bib43])   53 (25 : 75)            59.0          p16         80 (28/35)       5-year OS: *P*=0.01. HR 4.5 (95% CI 1.4--15)              5-year PFS: *P* = 0.006. HR 8.4 \[95% CI 1.8--38.6\]   Very high AQUA score (\>244) associated with higher incidence of local or distant recurrence (*P* = 0.004)   
  [@bib47]                               143 (26 : 74)           51.2          HPV         87.6 (120/137)   5-year OS: *P* = 0.036. 74% *vs* 52%                      N/A                                                    N/A                                                                                                          N/A
                                                                               p16         92.9 (131/141)   5-year OS: *P* \< 0.001. 76% *vs* 30%                     N/A                                                    N/A                                                                                                          N/A
  [@bib42]                               95 (43 : 57)            40.0          HPV16       95.8 (91/95)     10-year OS: *P* = 0.020. HR 2.86 (95% CI 1.1--7.1)        N/A                                                    Local failure rate: *P* = 0.023.                                                                             NS
                                                                               p16         65.2 (62/95)     NS                                                        N/A                                                    Local failure rate: *P* = 0.021.                                                                             NS
                                                                               HPV16 p16   U                10-year OS: *P* = 0.031.                                  N/A                                                    Local failure rate: *P* = 0.019.                                                                             N/A
  [@bib30]                               107 (47 : 53)           30.0          HPV         87.0 (93/107)    3-year OS: *P* \<0.001. 87% *vs* 35%                      N/A                                                    3-year TTLF rate: *P* \< 0.001. 82% *vs* 15%                                                                 NS
                                                                               p16         91.0 (97/107)    NS                                                        N/A                                                    3-year TTLF rate: *P*\<0.078. 75% *vs* 15%                                                                   NS
  [d](#t1-fn6){ref-type="fn"}[@bib1]     110 (43 : 57)           28.0          HPV16       85.0 (93/110)    5-year OS: *P* = 0.019. 59% *vs* 38%                      5-year RFS: *P*=0.027. 62% *vs* 40%                    N/A                                                                                                          N/A
                                                                               p16         89.0 (98/110)    5-year OS: *P* \< 0.001. 63% *vs* 13%                     5-year RFS: *P*\<0.001. 65% *vs* 16%                   N/A                                                                                                          N/A
  [@bib26]                               106 (41 : 59)    48.0 (LC) 54.0 (OS)  HPV p16     59.0 (63/106)    5-year OS: *P* = 0.011. 81.1% *vs* 68.8%                  N/A                                                    5-year LC: *P* = 0.002. 88.1% *vs* 55.8%                                                                     N/A

Abbreviations: HR, hazard ratio; HPV, human papilloma viruses; NA, not available/reported; NS, not significant; OS, overall survival; PFS, progression free survival; TTLF, time to locoregional failure; TTSF, time to systemic failure

Outcomes from univariate analyses are shown. Key: OS -- time from the date of diagnosis to the date of death from any cause; PFS -- time from the date of diagnosis/first day of treatment to the first documented date of progression; TTLF -- time from the first day of treatment to the first documented date of disease progression; TTSF -- time from the first day of treatment to the first documented distant metastasis. HR, provided here when univariate comparisons not available from text.

Statistically significant comparisons shown. All positive *vs* negative unless otherwise stated.

Subjects for whom biomarker positivity could be assessed.

'High risk\' deemed as high p16 expression and either the detection, or high levels of, HPV DNA.

Overlapping cohort of patients.

Data relate to patients with a pre-treatment haemoglobin of 120 g l^−1^. Lower pre-treatment haemoglobin was identified as an independent prognostic factor for poorer OS and PFS.
